Company profile: Pepscan
1.1 - Company Overview
Company description
- Provider of peptide R&D and production services, employing protein mimicry techniques and patented technologies. Offerings include peptide libraries, CLIPS technology, personalized neoantigen peptide pools, epitope mapping, and custom peptide synthesis with modifications, plus phage display and lead optimization at an end-to-end facility in Lelystad, the Netherlands.
Products and services
- CLIPS Technology: Proprietary peptide-constraining system that locks sequences in active conformations to drive lead discovery, lead optimization, and antibody epitope mapping using protein mimicry techniques
- Custom Peptide Synthesis: End-to-end service that produces tailored peptides with cyclization, PEGylation, and biotinylation modifications at Lelystad, Netherlands, supporting research and specialty applications
- Peptide Libraries: Custom-synthesized libraries for bioactivity screening, T-cell epitope mapping, and biochemical studies, offering a range of peptide modifications tailored to experimental needs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pepscan
Idaho Molecular
HQ: United States
Website
- Description: Provider of devices that help labs, hospitals, and research facilities make data driven decisions, using biotechnology to improve human lives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Idaho Molecular company profile →
Araris Biotech
HQ: Switzerland
Website
- Description: Provider of proprietary peptide linker technology for efficient payload attachment without antibody engineering, enabling creation of stable, homogenous, highly soluble antibody-drug conjugates (ADCs) with improved therapeutic efficacy and reduced side effects; also offers ADC development using off-the-shelf antibodies to deliver drugs to cancer cells with improved stability and solubility in a cost-effective manner.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Araris Biotech company profile →
Avalyn Pharma
HQ: United States
Website
- Description: Provider of inhaled therapies for idiopathic pulmonary fibrosis and other respiratory diseases, advancing direct-lung delivery candidates including AP01 (Phase 2b-ready inhaled pirfenidone), AP02 (reformulated inhaled nintedanib; Phase 1a completed), AP02-DP (dry powder nintedanib with equivalent pulmonary bioavailability), AP03 (fixed-dose inhaled pirfenidone+nintedanib), and AP04 (inhaled imatinib for PAH).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avalyn Pharma company profile →
Semba Biosciences
HQ: United States
Website
- Description: Provider of innovative instruments, reagents, methods, and solutions for high-performance purification of biomolecules and chemicals, serving the worldwide research community.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Semba Biosciences company profile →
Tissue Solutions
HQ: United Kingdom
Website
- Description: Provider of rapid, ethically compliant access to high-quality biospecimens via a virtual biobank offering a single point of access to diseased and normal human biomaterials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tissue Solutions company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pepscan
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pepscan
2.2 - Growth funds investing in similar companies to Pepscan
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pepscan
4.2 - Public trading comparable groups for Pepscan
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →